Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series

Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer

(2022) Youjun Deng et al.   ANTI-CANCER DRUGS

Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer

(2022) Hiroaki Satoh et al.   ANTI-CANCER DRUGS

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance

(2022) Qingli Cui et al.   Frontiers in Pharmacology

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer

(2022) Hong Jian et al.   ONCOLOGIST

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

(2022) Yubo Wang et al.   Frontiers in Oncology

Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report

(2022) Pei Ma et al.   ANTI-CANCER DRUGS

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS

(2022) Ying Li et al.   MOLECULES

Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review

(2022) Qianqian Zhang et al.   Frontiers in Endocrinology

Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis

(2022) Fei Yang et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China

(2021) Weize Lv et al.   Frontiers in Oncology

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)

(2021) Jingyi He et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review

(2021) Longqiu Wu et al.   Annals of Translational Medicine

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer

(2021) J.U. Lim   CLINICAL ONCOLOGY

Belzutifan: First Approval

(2021) Emma D. Deeks   DRUGS

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation

(2021) Gang Shen et al.   Frontiers in Pharmacology

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

(2021) Shun Lu et al.   Journal of Thoracic Oncology

Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials

(2020) Fang Yang et al.   JAMA Network Open

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

(2020) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Mechanisms of osimertinib resistance and emerging treatment options

(2020) Sabine Schmid et al.   LUNG CANCER

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations

(2020) Guang-Jian Yang et al.   LUNG CANCER

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

(2017) Kari Chansky et al.   Journal of Thoracic Oncology